Searle/FDA Cytotec Labeling Negotiations Continue Ahead Of Mifeprex Launch
Executive Summary
FDA is continuing to negotiate with Searle regarding changes to labeling of its gastric ulcer treatment Cytotec (misoprostol), which is an essential component of the recently approved Mifeprex (mifepristone, RU-486) regimen for termination of pregnancy.